Brought to you by 
Zogenix secures $30mm in cash from Cowen in exchange for royalties
13 Sep 2018
Executive Summary
Zogenix Inc. has received $30mm in cash from Cowen Healthcare Royalty Partners II LP. The neurology drug company will repay the debt using a percentage of product sales and co-promotion and out-licensing revenues from its migraine and headache treatment Sumavel DosePro (which is partnered with Astellas in the US), and future drugs including chronic pain candidate Zohydro (hydrocodone; formerly ZX002), which is finishing up Phase III and could be filed for approved in early 2012. The transaction will expire on March 31, 2018.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zogenix secures $30mm in cash from Cowen in exchange for royalties
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice